SKSakari Kauppinen

Sakari Kauppinen

*This is an algorithmically generated author record based on publicly available information.

Sakari Kauppinen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications

    by Clara Mayer, Lluís Riera-Ponsati, Sakari Kauppinen, Henrik Klitgaard, Janine T. Erler, Stine N. Hansen

    Neurodegenerative diseases constitute a global health issue and a major economic burden. They significantly impair both cognitive and motor functions, and their prevalence is expected to rise due to ageing societies and continuous population growth. Conventional therapies provide symptomatic relief, nevertheless, disease-modifying treatments that reduce or halt neuron death and malfunction are still largely unavailable. Amongst the common hallmarks of neurodegenerative diseases are protein aggregation, oxidative stress, neuroinflammation and mitochondrial dysfunction. Transcription factor nuclear factor-erythroid 2-related factor 2 (NRF2) constitutes a central regulator of cellular defense mechanisms, including the regulation of antioxidant, anti-inflammatory and mitochondrial pathways, making it a highly attractive therapeutic target for disease modification in neurodegenerative disorders. Here, we describe the role of NRF2 in the common hallmarks of neurodegeneration, review the current pharmacological interventions and their challenges in activating the NRF2 pathway, and present alternative therapeutic approaches for disease modification.


  • RNA therapeutics for epilepsy: An emerging modality for drug discovery

    by Stine N. Hansen, Anja Holm, Sakari Kauppinen, Henrik Klitgaard

    Drug discovery in epilepsy began with the finding of potassium bromide by Sir Charles Locock in 1857. The following century witnessed the introduction of phenotypic screening tests for discovering antiseizure medications (ASMs). Despite the high success rate of developing ASMs, they have so far failed in eliminating drug resistance and in delivering disease‐modifying treatments. This emphasizes the need for new drug discovery strategies in epilepsy. RNA‐based drugs have recently shown promise as a new modality with the potential of providing disease modification and counteracting drug resistance in epilepsy. RNA therapeutics can be directed either toward noncoding RNAs, such as microRNAs, long noncoding RNAs (ncRNAs), and circular RNAs, or toward messenger RNAs. The former show promise in sporadic, nongenetic epilepsies, as interference with ncRNAs allows for modulation of entire disease pathways, whereas the latter seem more promising in monogenic childhood epilepsies. Here, we describe therapeutic strategies for modulating disease‐associated RNA molecules and highlight the potential of RNA therapeutics for the treatment of different patient populations such as sporadic, drug‐resistant epilepsy, and childhood monogenic epilepsies.


  • Open Access

    Data from Silencing of the miR-17∼92 Cluster Family Inhibits Medulloblastoma Progression

    by Brian L. Murphy, Susanna Obad, Laure Bihannic, Olivier Ayrault, Frederique Zindy, Sakari Kauppinen, Martine F. Roussel

    Medulloblastoma, originating in the cerebellum, is the most common malignant brain tumor in children. Medulloblastoma consists of four major groups where constitutive activation of the Sonic Hedgehog (SHH) signaling pathway is a hallmark of one group. Mouse and human SHH medulloblastomas exhibit increased expression of microRNAs encoded by the miR-17∼92 and miR-106b∼25 clusters compared with granule progenitors and postmitotic granule neurons. Here, we assessed the therapeutic potential of 8-mer seed-targeting locked nucleic acid (LNA)-modified anti-miR oligonucleotides, termed tiny LNAs, that inhibit microRNA seed families expressed by miR-17∼92 and miR-106b∼25 in two mouse models of SHH medulloblastomas. We found that tumor cells (medulloblastoma cells) passively took up 8-mer LNA-anti-miRs and specifically inhibited targeted microRNA seed-sharing family members. Inhibition of miR-17 and miR-19a seed families by anti-miR-17 and anti-miR-19, respectively, resulted in diminished tumor cell proliferation in vitro. Treatment of mice with systemic delivery of anti-miR-17 and anti-miR-19 reduced tumor growth in flank and brain allografts in vivo and prolonged the survival of mice with intracranial transplants, suggesting that inhibition of the miR-17∼92 cluster family by 8-mer LNA-anti-miRs might be considered for the treatment of SHH medulloblastomas. Cancer Res; 73(23); 7068–78. ©2013 AACR.

  • Open Access

    Supplementary Figure Legend from Silencing of the miR-17∼92 Cluster Family Inhibits Medulloblastoma Progression

    by Brian L. Murphy, Susanna Obad, Laure Bihannic, Olivier Ayrault, Frederique Zindy, Sakari Kauppinen, Martine F. Roussel

  • Open Access

    Supplementary Methods from Silencing of the miR-17∼92 Cluster Family Inhibits Medulloblastoma Progression

    by Brian L. Murphy, Susanna Obad, Laure Bihannic, Olivier Ayrault, Frederique Zindy, Sakari Kauppinen, Martine F. Roussel

    PDF file - 62K, Confocal microscopy was performed using a confocal/multiphoton microscope.

  • Open Access

    Supplementary Figure Legend from Silencing of the miR-17∼92 Cluster Family Inhibits Medulloblastoma Progression

    by Brian L. Murphy, Susanna Obad, Laure Bihannic, Olivier Ayrault, Frederique Zindy, Sakari Kauppinen, Martine F. Roussel

  • Open Access

    Inhibition of microRNA function by antimiR oligonucleotides

    by Jan Stenvang, Andreas Petri, Morten Lindow, Susanna Obad, Sakari Kauppinen

    MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of gene expression in many developmental and cellular processes. Moreover, there is now ample evidence that perturbations in the levels of individual or entire families of miRNAs are strongly associated with the pathogenesis of a wide range of human diseases. Indeed, disease-associated miRNAs represent a new class of targets for the development of miRNA-based therapeutic modalities, which may yield patient benefits unobtainable by other therapeutic approaches. The recent explosion in miRNA research has accelerated the development of several computational and experimental approaches for probing miRNA functions in cell culture and in vivo. In this review, we focus on the use of antisense oligonucleotides (antimiRs) in miRNA inhibition for loss-of-function studies. We provide an overview of the currently employed antisense chemistries and their utility in designing antimiR oligonucleotides. Furthermore, we describe the most commonly used in vivo delivery strategies and discuss different approaches for assessment of miRNA inhibition and potential off-target effects. Finally, we summarize recent progress in antimiR mediated pharmacological inhibition of disease-associated miRNAs, which shows great promise in the development of novel miRNA-based therapeutics.


  • Silencing of microRNA families by seed-targeting tiny LNAs

    by Susanna Obad, Camila O dos Santos, Andreas Petri, Markus Heidenblad, Oliver Broom, Cristian Ruse, Cexiong Fu, Morten Lindow, Jan Stenvang, Ellen Marie Straarup, et al.

    Sakari Kauppinen and colleagues report a method for silencing miRNA families in vivo. They find that seed-targeting 8-mer LNA oligonucleotides, termed tiny LNAs, can lead to long-term miRNA silencing in normal tissues and breast tumors in mice. The challenge of understanding the widespread biological roles of animal microRNAs (miRNAs) has prompted the development of genetic and functional genomics technologies for miRNA loss-of-function studies. However, tools for exploring the functions of entire miRNA families are still limited. We developed a method that enables antagonism of miRNA function using seed-targeting 8-mer locked nucleic acid (LNA) oligonucleotides, termed tiny LNAs. Transfection of tiny LNAs into cells resulted in simultaneous inhibition of miRNAs within families sharing the same seed with concomitant upregulation of direct targets. In addition, systemically delivered, unconjugated tiny LNAs showed uptake in many normal tissues and in breast tumors in mice, coinciding with long-term miRNA silencing. Transcriptional and proteomic profiling suggested that tiny LNAs have negligible off-target effects, not significantly altering the output from mRNAs with perfect tiny LNA complementary sites. Considered together, these data support the utility of tiny LNAs in elucidating the functions of miRNA families in vivo.


  • Open Access

    miRMaid: a unified programming interface for microRNA data resources

    by Anders Jacobsen, Anders Krogh, Sakari Kauppinen, Morten Lindow

    MicroRNAs (miRNAs) are endogenous small RNAs that play a key role in post-transcriptional regulation of gene expression in animals and plants. The number of known miRNAs has increased rapidly over the years. The current release (version 14.0) of miRBase, the central online repository for miRNA annotation, comprises over 10.000 miRNA precursors from 115 different species. Furthermore, a large number of decentralized online resources are now available, each contributing with important miRNA annotation and information. We have developed a software framework, designated here as miRMaid, with the goal of integrating miRNA data resources in a uniform web service interface that can be accessed and queried by researchers and, most importantly, by computers. miRMaid is built around data from miRBase and is designed to follow the official miRBase data releases. It exposes miRBase data as inter-connected web services. Third-party miRNA data resources can be modularly integrated as miRMaid plugins or they can loosely couple with miRMaid as individual entities in the World Wide Web. miRMaid is available as a public web service but is also easily installed as a local application. The software framework is freely available under the LGPL open source license for academic and commercial use. miRMaid is an intuitive and modular software platform designed to unify miRBase and independent miRNA data resources. It enables miRNA researchers to computationally address complex questions involving the multitude of miRNA data resources. Furthermore, miRMaid constitutes a basic framework for further programming in which microRNA-interested bioinformaticians can readily develop their own tools and data sources.


  • Open Access

    Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF

    by Jesper Worm, Jan Stenvang, Andreas Petri, Klaus Stensgaard Frederiksen, Susanna Obad, Joacim Elmén, Maj Hedtjärn, Ellen Marie Straarup, Jens Bo Hansen, Sakari Kauppinen

    MicroRNA-155 (miR-155) has been implicated as a central regulator of the immune system, but its function during acute inflammatory responses is still poorly understood. Here we show that exposure of cultured macrophages and mice to lipopolysaccharide (LPS) leads to up-regulation of miR-155 and that the transcription factor c/ebp Beta is a direct target of miR-155. Interestingly, expression profiling of LPS-stimulated macrophages combined with overexpression and silencing of miR-155 in murine macrophages and human monocytic cells uncovered marked changes in the expression of granulocyte colony-stimulating factor (G-CSF), a central regulator of granulopoiesis during inflammatory responses. Consistent with these data, we show that silencing of miR-155 in LPS-treated mice by systemically administered LNA-antimiR results in derepression of the c/ebp Beta isoforms and down-regulation of G-CSF expression in mouse splenocytes. Finally, we report for the first time on miR-155 silencing in vivo in a mouse inflammation model, which underscores the potential of miR-155 antagonists in the development of novel therapeutics for treatment of chronic inflammatory diseases.